Provided by Tiger Trade Technology Pte. Ltd.

Cadrenal Therapeutics, Inc.

5.70
+0.36006.74%
Post-market: 5.810.1100+1.93%18:52 EST
Volume:45.43K
Turnover:263.39K
Market Cap:13.33M
PE:-0.70
High:6.01
Open:5.49
Low:5.49
Close:5.34
52wk High:22.90
52wk Low:5.34
Shares:2.34M
Float Shares:1.81M
Volume Ratio:0.96
T/O Rate:2.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.1896
EPS(LYR):-8.7339
ROE:-468.03%
ROA:-209.23%
PB:4.87
PE(LYR):-0.65

Loading ...

Company Profile

Company Name:
Cadrenal Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2022
Employees:
4
Office Location:
822 A1A North,Suite 306,Ponte Vedra,Florida,United States
Zip Code:
32082
Fax:
- -
Introduction:
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Directors

Name
Position
Quang Pham
Chairman and CEO
Glynn Wilson
Director
John Raymond Murphy
Director
Lee Scott Golden
Director
Steven Zelenkofske
Director

Shareholders

Name
Position
Jeffrey Cole
Chief Operating Officer
Matthew Szot
Chief Financial Officer
James J. Ferguson, III
Chief Medical Officer
Quang Pham
Chairman and CEO